Patent application number | Description | Published |
20090239938 | PREVENTIVE/REMEDY FOR ARTERIOSCLEROSIS - A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. | 09-24-2009 |
20090291461 | METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS - Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody. | 11-26-2009 |
20100098720 | Substance preventing adverse actions of therapeutic agents for dyslipidemia - A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from | 04-22-2010 |
20100273708 | ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF - The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases. | 10-28-2010 |
20100303855 | METHOD OF REDUCING ADVERSE EFFECTS OF THERAPEUTIC AGENTS FOR DYSLIPIDEMIA - A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from | 12-02-2010 |
20110151456 | TEST METHOD FOR TYPE-2 DIABETES USING GENE POLYMORPHISM - The present invention relates to a method of testing for genetic susceptibility to type-2 diabetes in a subject that comprises detecting one or more polymorphisms present in the KCNQ1 gene and/or EIF2AK4 gene in a DNA-containing sample collected from the subject. The present invention permit a method of accurately, conveniently, and rapidly testing the genetic susceptibility of subjects to type-2 by targeting determinative genetic factors of genetic susceptibility to type-2 diabetes. | 06-23-2011 |
20130143748 | METHODS FOR DETECTION OF RISK OF OBESITY AND RISK OF ONSET OF DIABETES - Provided is a method of measuring the expression level of FSTL3 gene in a biological sample and correlating the measured expression level with the detection of a risk of developing diabetes. Also provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 not clinically determined as obesity and correlating the measured expression level with the detection of a risk of developing obesity. Further provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 and correlating the measured expression level with the detection of a risk of developing diabetes. Further provided is a method of measuring an inhibin βB gene expression level and correlating the ratio of expression level of FSTL3 gene to inhibin βB gene with the detection of a risk of developing obesity or diabetes. | 06-06-2013 |
20130143812 | ANTI-INFLAMMATORY DRUG - Provided is a new anti-inflammatory drug that produces an anti-inflammatory effect by modulating macrophage function. Specifically, a new anti-inflammatory drug that produces an anti-inflammatory effect through induction of M2 macrophages using activin species is provided. | 06-06-2013 |
20130236893 | METHOD OF DETECTING TYPE II DIABETES - A single-nucleotide polymorphism in the UBE2E2 locus or C2CD4A-C2CD4B locus is analyzed and type II diabetes is examined based on the results of the analysis. | 09-12-2013 |